Renowned cancer researcher Dr. Daniel Von Hoff and his team at TGen are fervent believers in a new approach to developing novel therapies for patients with pancreatic cancer. They are guided by a rationale dubbed the "context of vulnerability." Dr. Von Hoff provides case studies and explains how this powerful paradigm has already led to promising discoveries and is changing the future of oncology drug development. The complete interview is available for download from Medelis, an oncology contract research organization providing worldwide oncology clinical trial design, management and execution.
Phoenix, AZ (PRWEB) February 17, 2009 -- Today, Medelis, Inc., a global oncology contract research organization, has published a free new downloadable abstract, "Context of Vulnerability: A Powerful New Paradigm for Targeted Drug Development." In this extensive interview, renowned oncology investigator Daniel D. Von Hoff, M.D., a founder of Medelis and a member the National Cancer Advisory Board, advocates for this powerful new drug development paradigm that is generating impressive results in the war on pancreatic cancer, the most deadly of all cancers.
"People say we have lost the war on cancer and it is so discouraging to the people who deliver the care every day, the people who are seeing those curves turn around," laments Dr. Von Hoff. "The fact is that the rising tide of cancer deaths hasn't just been stemmed - it's been turned around. Mortality, in terms of abso
'/>"/>
| Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved |